KMC Hospital in Mangaluru successfully treats Rev Fr Wolfgang Leonhard, a German priest, diagnosed with hypertrophic obstructive cardiomyopathy and complete heart block. The cardiology team implanted ...
The San Francisco-based drugmaker recently launched a campaign to educate healthcare professionals (HCP) about hypertrophic ...
View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...
Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.
The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...
Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...
Analyst Roanna Ruiz of Leerink Partners maintained a Buy rating on Cytokinetics (CYTK – Research Report), reducing the price target to ...
Aficamten, targeted at obstructive hypertrophic cardiomyopathy (oHCM), has completed NDA submissions ... which focuses on the discovery and development of muscle activators as potential treatment for ...
Dr. Eugene Braunwald is often called the father of modern cardiology. He calls that an exaggeration. "Maybe I've been around ...
In patients with obstructive hypertrophic cardiomyopathy, aficamten is associated with improvements ... These results underscore the wide-ranging potential of aficamten for treatment of patients with ...
Background: Mavacamten, a cardiac myosin inhibitor, is approved across 5 continents for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Long-term data of mavacamten are available from ...
With the right, science-approved scar creams, treating old and new scars can be a breeze. These are our favourites.